Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant S-1 plus oxaliplatin for locally advanced gastric or esophagogastric junction adenocarcinoma (KSCC1601)
jRCTs071180064Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Jun 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Yakult Honsha. Primary endpoint: pathological response rate (pRR). Started Jun 2016; status: completed.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs071180064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180064.